| Literature DB >> 30362387 |
Dilek Canakci1, Ismail Koyuncu2, Nabih Lolak3, Mustafa Durgun4, Suleyman Akocak3, Claudiu T Supuran5.
Abstract
In this study, a series of 10 novel copper (II) andEntities:
Keywords: Metal complexes; cancer cells; cytotoxicity; sulfonamides; triazene
Mesh:
Substances:
Year: 2019 PMID: 30362387 PMCID: PMC6211257 DOI: 10.1080/14756366.2018.1530994
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051
Scheme 1.General binding modes of triazene ligands.
Scheme 2.General synthetic route of the novel copper (a) and silver (b) complexes.
The UV–Vis spectra data of 1,3-diaryltriazene ligands and metal complexes.
| A | B | C | D | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Compounds | |||||||||
| L1 | 233 | 0.389 | 309 | 3.289 | 360 | 3.148 | 401 | 2.637 | 3.133 |
| L2 | 260 | 3.585 | 289 | 3.937 | 366 | 2.652 | 420 | 2.792 | 2.961 |
| L3 | 254 | 1.629 | 303 | 3.547 | 360 | 3.323 | 416 | 2.949 | 2.990 |
| L4 | 254 | 1.561 | 273 | 0.486 | 341 | 1.500 | 496 | 1.442 | 2.507 |
| L5 | 255 | 2.881 | 294 | 3.730 | 341 | 1.503 | 497 | 3.374 | 2.502 |
| L1-Cu | 262 | 3.850 | 288 | 4.663 | 353 | 2.914 | 427 | 2.641 | 2.913 |
| L2-Cu | 254 | 2.294 | 303 | 3.645 | 360 | 3.399 | 461 | 4.364 | 2.698 |
| L3-Cu | 234 | 3.842 | 281 | 5.273 | 361 | 3.113 | 422 | 2.819 | 2.947 |
| L4-Cu | 260 | 1.448 | 309 | 3.142 | 363 | 3.020 | 453 | 3.145 | 2.745 |
| L5-Cu | 222 | 4.383 | 279 | 6.561 | 366 | 2.474 | 411 | 2.581 | 3.026 |
| L1-Ag | 248 | 4.537 | 287 | 5.096 | – | – | 438 | 4.104 | 2.839 |
| L2-Ag | 247 | 1.996 | 285 | 1.913 | – | – | 447 | 3.286 | 2.782 |
| L3-Ag | 268 | 3.483 | 312 | 3.529 | 359 | 3.332 | 423 | 3.177 | 2.940 |
| L4-Ag | 256 | 2.154 | 293 | 3.676 | – | – | 531 | 3.373 | 2.342 |
| L5-Ag | 259 | 2.846 | 292 | 2.540 | 367 | 2.857 | 480 | 3.509 | 2.591 |
λmax: the wavelength at the absorption maxima(nm); εmax: molar absoptivity coefficient(L/mol cm); ECT: charge transfer energy(eV).
Cytotoxicity of ligands L1-5, metal complexes of L1-5 Cu, L1-5 Ag and 5-fluorouracil (5-FU) on tumor cell lines and normal cell lines.
| Compound | IC50 (µM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cancer cell | Normal cell | |||||||||
| DLD-1 | HeLa | MDA-MB-231 | HT-29 | ECC-1 | DU-145 | PC-3 | HEK-293 | PNT-1A | ARPE-19 | |
| L1 | 139.8 ± 11.0 | 178.8 ± 16 | 104.1 ± 28.2 | 79.4 ± 15.4 | 239.4 ± 27.5 | 29.0 ± 2.9 | 168.2 ± 18.5 | 131.7 ± 16.4 | 194.9 ± 23.5 | 279.2 ± 33.8 |
| L2 | 223.0 ± 8.3 | 768 ± 6.5 | 144.4 ± 2.4 | 265.2 ± 30 | >300 | 154.4 ± 25.6 | 170.6 ± 20.5 | 145.7 ± 13.4 | >300 | >300 |
| L3 | >300 | >300 | >300 | >300 | 197.0 ± 23.5 | 186.5 ± 20.6 | >300 | >300 | >300 | >300 |
| L4 | >300 | >300 | 155.1 ± 2.6 | >300 | >300 | 181.9 ± 23.4 | 299.4 ± 32.3 | >300 | 237.1 ± 26.8 | >300 |
| L5 | 223.6 ± 12.4 | 65.1 ± 4.5 | 144.1 ± 18.6 | 111.6 ± 16.5 | 131.6 ± 13.1 | 97.8 ± 9.7 | 131.0 ± 12.4 | 102.7 ± 10.2 | 177.4 ± 20.5 | >300 |
| L1-Cu | 47.1 ± 4.7 | 5.0 ± 0.4 | 116.8 ± 14.2 | 198.9 ± 24.3 | 26.2 ± 2.6 | 104.9 ± 13.5 | 102.0 ± 10.2 | 68.8 ± 8.7 | 76.5 ± 8.5 | 119.0 ± 13.5 |
| L2-Cu | 42.7 ± 3.3 | 2.1 ± 0.1 | 50.0 ± 2.4 | 94.9 ± 9.4 | 39.5 ± 2.5 | 116.4 ± 14.6 | 65.3 ± 8.5 | 159.2 ± 19.4 | 95.1 ± 11.1 | 131.7 ± 15.6 |
| L3-Cu | 65.2 ± 2.5 | 63.9 ± 4.3 | 48.3 ± 2.5 | 205.1 ± 20.3 | 362.1 ± 38.1 | 58.3 ± 6.4 | 196.4 ± 22.6 | 134.7 ± 15.6 | 119.5 ± 13.5 | >300 |
| L4-Cu | 58.4 ± 5.8 | 115.8 ± 9.2 | 205.5 ± 25.1 | 198.7 ± 22.5 | 307.5 ± 34.2 | 160.5 ± 18.0 | 296.8 ± 32.4 | 196.8 ± 23.5 | 125.1 ± 14.8 | 105.2 ± 13.5 |
| L5-Cu | 58.8 ± 3.9 | 15.2 ± 1.0 | 26.0 ± 2.5 | 84.4 ± 8.4 | 97.6 ± 9.7 | 32.4 ± 3.2 | 79.2 ± 8.5 | 36.3 ± 3.6 | 46.4 ± 4.6 | 84.3 ± 8.4 |
| L1-Ag | 279.3 ± 12.9 | >300 | 96.8 ± 9.6 | 185.7 ± 16.5 | 207.0 ± 25.6 | 136.7 ± 16.5 | 612.0 ± 61.2 | >300 | 209.7 ± 20.9 | >300 |
| L2-Ag | 31.6 ± 3.2 | 2.8 ± 0.1 | 30.3 ± 3.0 | 24.9 ± 2.5 | 29.1 ± 3.0 | 18.6 ± 1.8 | 28.2 ± 3.5 | 17.8 ± 1.7 | 17.5 ± 17.5 | 22.0 ± 10.2 |
| L3-Ag | 3.3 ± 0.3 | 3.4 ± 0.2 | 9.8 ± 0.9 | 10.1 ± 3.1 | 16.2 ± 1.6 | 4.8 ± 0.4 | 5.1 ± 0.5 | 9.9 ± 0.9 | 9.2 ± 0.9 | 9.5 ± 0.9 |
| L4-Ag | 173.3 ± 10.3 | 139.3 ± 28 | >300 | 240.7 ± 28.5 | 103.6 ± 10.3 | 236.7 ± 28.5 | 136.6 ± 15.8 | 5.5 ± 0.6 | 139.1 ± 16.5 | 284.8 ± 30.5 |
| L5-Ag | 110.7 ± 9.0 | 9.6 ± 0.6 | 148.4 ± 19.5 | 161.6 ± 16.1 | 135.9 ± 13.5 | 100.3 ± 10.1 | 111.7 ± 13.4 | 30.5 ± 4.5 | 110.8 ± 11.0 | 109.4 ± 11.0 |
| 5-FU | 50.2 ± 21.0 | 19.2 ± 1.2 | 22.4 ± 2.5 | 24.2 ± 2.4 | 30.6 ± 3.5 | 37.3 ± 5.8 | 45.5 ± 4.5 | 65.3 ± 8.6 | 142.3 ± 18.6 | 75.3 ± 7.5 |
Values are means of three independent experiments.
IC50 values determined at 48 h.
Figure 1.Plot of viable cells at various concentrations of L1 against DU-145 tumor cells and PNT-1A normal cell line.
Figure 2.Plot of viable cells at various concentrations of L2-Cu against HeLa tumor cells and ARPE-19 normal cell line.
Figure 3.Plot of viable cells at various concentrations of L2-Ag against HeLa tumor cells and ARPE-19 normal cell line.